Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
33 /100
MEDIUM RISK
Score updated Aug 28, 2026

MNPR — Monopar Therapeutics Inc. Dilution Risk Tracker

Track MNPR dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track MNPR — Get alerts when the score changes →

As of August 28, 2026, Monopar Therapeutics Inc. (MNPR) has a DilutionWatch DilutionScore of 33/100, rated MEDIUM dilution risk. Monopar Therapeutics Inc. has a market capitalization of $435.71M, 6.71M shares outstanding, 82 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
0
📊 Float Risk
40
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for MNPR.
🔔 Track MNPR — Get forecast alerts →

Market Data

Market Cap$435.71M
Shares Outstanding6.71M
Float4.13M
Cash$52.76M
Debt$230.4K
Short InterestN/A

Institutional Holdings

QoQ: ↑ 38.8% shares (2026Q1 vs prior)
82 institutional holders · 8.00M shares
#1 JANUS HENDERSON GROUP PLC 2.63M shares
#2 RA CAPITAL MANAGEMENT, L.P. 667.2K shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 436.9K shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest1.07M
Days to Cover3.4
% of Float25.8%
FINRA data as of Jul 31, 2026

Recent SEC Activity

4 INSIDER TRANSACTION 2026-04-02
4 INSIDER TRANSACTION 2026-04-02
3 FORM3 2026-03-04
4 INSIDER TRANSACTION 2026-03-04
4 INSIDER TRANSACTION 2026-01-30
Full SEC filing analysis available with free account

Recent News

No recent news

Factual MNPR Dilution Snapshot

Monopar Therapeutics Inc. (MNPR) has a DilutionScore of 33/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track MNPR Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking MNPR — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for MNPR
MNPR FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.